Briefly Bio

Briefly Bio is a London-based techbio startup that addresses the reproducibility crisis in scientific research. The company has developed software that uses artificial intelligence to help scientists capture and share their experimental work more clearly and consistently. Briefly Bio's platform converts existing experiment descriptions into a standardized format, automatically filling in gaps and identifying errors. This approach aims to create a shared language for experiments that is consistent across scientists and clear for collaborators to understand.

The software works by using large language models to structure plain text descriptions of procedural knowledge into a hierarchical representation. It extracts key information and categorizes it into processes, actions, explanations, and parameters. This structured representation is then transformed into a visual format that is easier to comprehend than traditional text descriptions. Additionally, Briefly Bio includes an AI copilot that can be prompted via natural language to spot errors and identify parameters related to the lab work.

Briefly Bio's solution is designed to tackle the estimated 50% failure rate in reproducing preclinical research experiments, which costs the industry over USD 50 billion annually. By improving the reproducibility of lab work, the company aims to enable more efficient and accurate scientific discoveries. The platform is particularly useful for wet lab scientists in early-stage research and development, both in academia and industry, as well as those working in laboratory automation.

Key customers and partnerships

Briefly Bio has already secured paying customers for its software-as-a-service business model. The company's target market includes biotechnology and pharmaceutical companies, with plans to offer access to academics and individual scientists at reduced prices or for free.